Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ520521-0,48
KB814,5816,50,68
PKN93,8893,980,38
Msft140,08140,160,00
Nokia4,65554,66050,56
IBM141,7142,590,00
Daimler AG47,60547,620,54
PFE36,2636,520,00
19.09.2019 10:48:55
Indexy online
AD Index online
select
AD Index online
 

  • 19.09.2019 10:43:40
CytoTools (T5OG.DE, Xetra)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
10,25 2,50 0,25 359
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.09.2019
Popis společnosti
Obecné informace
Název společnostiCytoTools AG
TickerT5O
Kmenové akcie:Ordinary Shares
RICT5OG.DE
ISINDE000A0KFRJ1
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky31.12.2018
Počet zaměstnanců k 31.12.2018 1
Akcie v oběhu k 06.03.2019 2 685 945
MěnaEUR
Kontaktní informace
UliceKlappacher Strasse 126
MěstoDARMSTADT
PSČ64285
ZeměGermany
Kontatní osoba 
Funkce kontaktní osoby 
Telefon4961 519 515 812
Fax4961519515813

Business Summary: CytoTools AG is a Germany-based investment and holding company active in the biotechnology sector. The Company holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. CytoTools AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections, and pre-clinical stage CardioClean for the treatment of restenosis, diabetis and carotis-stenosis.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2018, CytoTools AG revenues decreased from EUR90K to EUR0K. Net loss increased 33% to EUR1.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest Expenses increase from EUR59K to EUR251K (expense), Wages / Salaries increase of 41% to EUR426K (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSOwners and Lessors of Other Non-Financial Assets
NAICSOffices of Other Holding Companies
SICCommercial Physical Research
SICPatent Owners And Lessors
SICHolding Companies, Nec



  • Poslední aktualizace: 19.09.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardManfred May-22.05.200622.05.2006
Chairman of the Management Board, Chief Executive OfficerMark-Andre Freyberg-
Deputy Chairman of the Supervisory BoardPeter Friedl-09.08.201109.08.2011
Member of the Management Board, Chief Research OfficerDirk Kaiser-